A carregar...
Publicação
Private equity investment committee proposal - medpace valuation
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 256.17 KB | Adobe PDF |
Orientador(es)
Resumo(s)
Medpace is one of the world’s leading Contract Research
Organizations, by revenue, and it differentiates itself by focusing
on full-service clinical trials for small and mid-sized biopharma
clients. Its strong positioning in a niche market, the high projected
industry growth, its strong and stable FCFs, and experienced
management team make it an ideal target, which would be further
improved by our developed business plan that will enhance its
operations, expand internationally, and capitalize on M&A trends.
Our proposed transaction is expected to deliver a money multiple
of 3.28x and an IRR of 26.84%, representing a strong investment
opportunity.
Descrição
Palavras-chave
Contract research organization (Cro) Research & development (R&D) Mergers & acquisitions (M&A) Biopharma Leverage buyout (Lbo) Money Multiple (Mm) Internal rate of return (Irr)